| Literature DB >> 29285246 |
Ying Yue1,2,3, Mengjia Song1,2, Yamin Qiao1,2, Pupu Li1,2, Yiqiang Yuan3, Jingyao Lian1,2, Suying Wang4, Yi Zhang1,2,5,6.
Abstract
Esophageal cancer (EC) is one of the most common digestive malignant tumors worldwide. Over the past decades, there have been minimal improvements in outcomes for patients with EC. New targets and novel therapies are needed to improve outcomes for these patients. This study aimed to explore the molecular mechanisms of EC by integrated bioinformatic analyses of the feature genes associated with EC and correlative gene functions which can distinguish cancerous tissues from non-cancerous tissues. Gene expression profile GSE20347 was downloaded from Gene Expression Omnibus (GEO) database, including 17 EC samples and their paired adjacent non-cancerous samples. The differentially expressed genes (DEGs) between EC and normal specimens were identified and then applied to analyze the GO enrichment on gene functions and KEGG pathways. Corresponding Pathway Relation Network (Pathway-net) and Gene Signal Network (signal-net) of DEGs were established based on the data collected from GCBI datasets. The results showed that DEGs mainly participated in the process of cell adhesion, cell proliferation, survival, invasion, metastasis and angiogenesis. Aberrant expression of PTK2, MAPK signaling pathway, PI3K-Akt signaling pathway, p53 signaling pathway and MET were closely associated with EC carcinogenesis. Importantly, Interleukin 8 (IL8) and C-X-C chemokine receptor type 7 (CXCR-7) were predicted to be significantly related to EC. These findings were further validated by analyzing both TCGA database and our clinical samples of EC. Our discovery provides a registry of genes and pathways that are disrupted in EC, which has the potential to be used in clinic for diagnosis and target therapy of EC in future.Entities:
Keywords: esophagus cancer; gene function analysis; microarray gene expression profiling
Year: 2017 PMID: 29285246 PMCID: PMC5739633 DOI: 10.18632/oncotarget.22160
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Box plots of gene expression data of 17 EC and 17 normal tissues after standardization
(A) NUSE and (B) RLE of these data after standardization are within an acceptable range. Black lines in the boxes represent medians. Red lines in the boxes represent the standard criterion of RLE. NUSE, Normalized Unscaled Standard Errors. RLE, Relative Log Expression. EC, Esophageal cancer.
Figure 2Hierarchical cluster dendrogram of DEGs
The horizontal axis represents sample names. The brown part represents normal samples and the blue part represents EC samples. The left vertical axis shows clusters of DEGs, and the above horizontal axis shows clusters of samples. Red represents up-regulated genes and green represents down-regulated genes.
The top20 significant up-regulated and down-regulated DEGs involved in EC according to fold change
| Group | Gene Symbol | Gene Description | Fold Change | p-value |
|---|---|---|---|---|
| Upregulated genes | MMP1 | matrix metallopeptidase 1 (interstitial collagenase) | 33.299251 | 0.000199 |
| SPP1 | secreted phosphoprotein 1 | 24.812088 | 0.000105 | |
| COL11A1 | collagen, type XI, alpha 1 | 20.854271 | 0.000211 | |
| NTS | neurotensin | 15.378321 | 0.007374 | |
| POSTN | periostin, osteoblast specific factor | 13.764033 | 0.000511 | |
| ANO1 | anoctamin 1, calcium activated chloride channel | 13.329332 | 0.000648 | |
| MMP12 | matrix metallopeptidase 12 (macrophage elastase) | 12.706198 | 0.000068 | |
| VCAN | versican | 10.73413 | 0.000315 | |
| IL8 | interleukin 8 | 10.236861 | 0.000172 | |
| COL1A2 | collagen, type I, alpha 2 | 9.234818 | 0.001952 | |
| COL1A1 | collagen, type I, alpha 1 | 9.214333 | 0.001832 | |
| JUP | junction plakoglobin | 8.955021 | 0.001329 | |
| MMP10 | matrix metallopeptidase 10 (stromelysin 2) | 8.592152 | 0.002876 | |
| AKR1C1 | aldo-keto reductase family 1, member C1 | 8.546899 | 0.004894 | |
| SULF1 | sulfatase 1 | 7.965726 | 0.000175 | |
| ZIC1 | Zic family member 1 | 7.84641 | 0.000662 | |
| APOBEC3B | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B | 7.596131 | 0.000517 | |
| CDH11 | cadherin 11, type 2, OB-cadherin (osteoblast) | 7.206682 | 0.000612 | |
| INHBA | inhibin, beta A | 7.125975 | 0.001156 | |
| Downregulated genes | CRISP3 | cysteine-rich secretory protein 3 | −145.091859 | 0.000046 |
| CRNN | cornulin | −84.394306 | 0.000063 | |
| MAL | mal, T-cell differentiation protein | −57.860795 | 0.000076 | |
| CRCT1 | cysteine-rich C-terminal 1 | −49.533869 | 0.000079 | |
| TGM3 | transglutaminase 3 (E polypeptide, protein-glutamine-gamma-glutamyltransferase) | −47.423993 | 0.000069 | |
| SCEL | sciellin | −41.055178 | 0.00006 | |
| CLCA4 | chloride channel accessory 4 | −40.459777 | 0.000113 | |
| CLIC3 | chloride intracellular channel 3 | −40.15493 | 0.000051 | |
| KRT4 | keratin 4 | −33.981117 | 0.000344 | |
| SLURP1 | secreted LY6/PLAUR domain containing 1 | −32.55029 | 0.000047 | |
| SPINK5 | serine peptidase inhibitor, Kazal type 5 | −32.391855 | 0.000058 | |
| TMPRSS11E | transmembrane protease, serine 11E | −24.154135 | 0.000129 | |
| ENDOU | endonuclease, polyU-specific | −23.847101 | 0.000045 | |
| HPGD | hydroxyprostaglandin dehydrogenase 15-(NAD) | −20.91442 | 0.000089 | |
| KLK13 | kallikrein-related peptidase 13 | −20.206265 | 0.00009 | |
| CEACAM7 | carcinoembryonic antigen-related cell adhesion molecule 7 | −19.141801 | 0.000169 | |
| FLG | filaggrin | −19.015206 | 0.000089 | |
| EREG | epiregulin | −18.937187 | 0.000046 | |
| CXCR2 | chemokine (C-X-C motif) receptor 2 | −17.054968 | 0.000046 | |
| PPP1R3C | protein phosphatase 1, regulatory subunit 3C | −17.054788 | 0.000047 | |
| KRT13 | keratin 13 | −16.592631 | 0.001601 | |
| CYP4B1 | cytochrome P450, family 4, subfamily B, polypeptide 1 | −16.56291 | 0.000102 |
Figure 3Gene Ontology enrichment analyses
The top 10 significantly up-regulated and down-regulated GO categories in EC based on the functional enrichment. The horizontal axis represents the enrichment score of DEGs. The vertical axis represents the GO categories.
Figure 4The top 10 significant pathways of the DEGs
The top 10 significantly changed pathways of up-regulated and down-regulated DEGs were shown respectively. The vertical axis is the pathway categories, and the horizontal axis is the negative logarithm of the P value (−LgP) of pathways.
Figure 5Pathway network (Path-net) analysis
Significantly changed pathways are connected in a Path-net to show the relationship between these pathways. Each pathway in the network is measured by counting the upstream and downstream pathways, which are shown as in-degree, out-degree or degree, respectively. A higher degree of pathway indicates that it regulates or is regulated by other pathways, implying a more important role in the signaling network. The yellow circle represents the both up-regulated and down-regulated pathway and the red represents the up-regulated pathway. The lines show the interaction between pathways.
The top10 significant pathways identified by pathway-net analysis of DEGs associated with EC according to degree number
| Pathway Name | Outdegree | Indegree | Degree |
|---|---|---|---|
| MAPK signaling pathway | 5 | 28 | 33 |
| Apoptosis | 3 | 21 | 24 |
| Pathways in cancer | 22 | 0 | 22 |
| Cell cycle | 2 | 17 | 19 |
| Calcium signaling pathway | 5 | 10 | 15 |
| p53 signaling pathway | 2 | 13 | 15 |
| Focal adhesion | 8 | 7 | 15 |
| Adherens junction | 6 | 9 | 15 |
| Wnt signaling pathway | 7 | 6 | 13 |
| Glycolysis / Gluconeogenesis | 2 | 10 | 12 |
Figure 6Signal network (Signal-net) analysis
The red circle represents the up-regulated DEGs and the blue circles down-regulated DEGs. The area of the circle represents the betweenness. Interaction between the genes is shown as a activation, a(b) activation(binding/association), a(ind) activation (indirect effect), a(p) activation(phosphorylation), a(ind)(p) activation(indirect effect)(phosphorylation), a(p)(ind) activation(phosphorylation)(indirect effect), c compound, ex expression, ex(ind) expression(indirect effect), ind indirect effect, inh(dep) inhibition(dephosphorylation), inh(u)(a) inhibition(ubiquitination)(activation), p(a) phosphorylation(activation).
The top10 significant DEGs identified by signal-net analysis in EC according to betweenness value
| Gene Symbol | Gene Feature | Betweenness | Indegree | Outdegree |
|---|---|---|---|---|
| PLCD1 | down | 10047.3333 | 7 | 7 |
| PIK3R1 | down | 9022.6167 | 16 | 5 |
| SULT2B1 | down | 7918 | 3 | 3 |
| IMPAD1 | up | 7889 | 3 | 3 |
| CYP3A5 | down | 7780.8183 | 9 | 9 |
| PTK2 | up | 6435.85 | 31 | 2 |
| MAPK13 | down | 5025.5 | 6 | 10 |
| GATM | down | 2820.75 | 4 | 4 |
| SHMT1 | down | 2627 | 3 | 3 |
| CXCR2 | down | 2377.2984 | 8 | 2 |
Figure 7Expression and survival significance of IL8 and CXCR7 in patients with EC
(A) IL8 mRNA relative expression in cancerous and their paired adjacent non-cancerous tissues in 30 patients with EC were analyzed by RT-PCR. (B) CXCR7 mRNA relative expression in cancerous and their paired adjacent normal tissues in 30 patients with EC were analyzed by RT-PCR. Kaplan-Meier survival curve for 30 EC patients with high (n=15) and low (n=15) IL8 (C) and CXCR7 (D) expression (RT-PCR analysis). (E) IL8 and CXCR7 expression in cancerous and paired adjacent normal tissue of EC were analyzed by IHC. (F) The final immunoreactivity score of IL8 and CXCR7 expression in 22 paired specimens was shown as statistical graph. (**P < 0.01; N, non-cancerous tissue; CA, cancerous tissue).